HDAC1 and diffuse large B-cell lymphoma: Following a 24h treatment, no significant increase in DNA damage was observed in EZH2GOF DLBCL cells treated with the HDAC1,2 selective inhibitor or the EZH2 inhibitors (data not shown), which agrees well with the lack of any defects in the cell cycle progression observed at this time point using these inhibitors (Supplementary Figure 2).